BioCardia first patient enrolled at Henry Ford Health for Phase 3 CardiAMP

BioCardia (BCDA) announced the first patient enrolled at Henry Ford Health in its ongoing Phase 3 CardiAMP HF II clinical trial for patients with ischemic heart failure of reduced ejection fraction. “The CardiAMP-HF trial, in which Henry Ford Health participated, was groundbreaking for the field of heart failure. Although the primary endpoint was not met, the study showed impressive results with an autologous cell therapy in patients with HFrEF, particularly those with elevated biomarkers of heart stress,” said Dr. Gerald Koenig, M.D., Director of the Cardiac Catheterization Laboratory at Henry Ford West Bloomfield Hospital and Director of Clinical Research in the Cardiac Catheterization Laboratory at Henry Ford Health System, and Principal Investigator in the Phase 3 CardiAMP HF II trial.